Bladder transitional cell carcinoma
Not recruitingStudy of Pembrolizumab and Sacituzumab Govitecan for Patients with Muscle-Invasive Bladder Cancer Unable or Unwilling to Use Cisplatin-Based Chemotherapy
Study of Pembrolizumab and Sacituzumab Govitecan for Patients with Muscle-Invasive Bladder Cancer Unable or Unwilling to Use Cisplatin-Based Chemotherapy
- Disease:Bladder transitional cell carcinoma
- Substances:PembrolizumabSacituzumab Govitecan
Italy- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Ospedale San Raffaele S.r.l.








